Cited by 160Medication Adherence and ComplianceTuberculosis Research and EpidemiologyMobile Health and mHealth Applications

Feasibility of an Ingestible Sensor-Based System for Monitoring Adherence to Tuberculosis Therapy

Open access
Belknap, Robert, Weis, Steve, Brookens, Andrew, Au-Yeung, Kit Yee, Moon, Greg, DiCarlo, Lorenzo, Reves, Randall·2013·PLoS ONE

Abstract

Poor adherence to tuberculosis (TB) treatment hinders the individual's recovery and threatens public health. Currently, directly observed therapy (DOT) is the standard of care; however, high sustaining costs limit its availability, creating a need for more practical adherence confirmation methods. Techniques such as video monitoring and devices to time-register the opening of pill bottles are unable to confirm actual medication ingestions. A novel approach developed by Proteus Digital Health, Inc. consists of an ingestible sensor and an on-body wearable sensor; together, they electronically confirm unique ingestions and record the date/time of the ingestion. A feasibility study using an early prototype was conducted in active TB patients to determine the system's accuracy and safety in confirming co-ingestion of TB medications with sensors. Thirty patients completed 10 DOT visits and 1,080 co-ingestion events; the system showed 95.0% (95% CI 93.5-96.2%) positive detection accuracy, defined as the number of detected sensors divided by the number of transmission capable sensors administered. The specificity was 99.7% [95% CI 99.2-99.9%] based on three false signals recorded by receivers. The system's identification accuracy, defined as the number of correctly identified ingestible sensors divided by the number of sensors detected, was 100%. Of 11 adverse events, four were deemed related or possibly related to the device; three mild skin rashes and one complaint of nausea. The system's positive detection accuracy was not affected by the subjects' Body Mass Index (p = 0.7309). Study results suggest the system is capable of correctly identifying ingestible sensors with high accuracy, poses a low risk to users, and may have high patient acceptance. The system has the potential to confirm medication specific treatment compliance on a dose-by-dose basis. When coupled with mobile technology, the system could allow wirelessly observed therapy (WOT) for monitoring TB treatment as a replacement for DOT.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0053373

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Belknap, R., Weis, S., Brookens, A., Au-Yeung, K. Y., Moon, G., DiCarlo, L., & Reves, R.
Affiliations
  • Denver Public Health (US)
  • University of Washington (US)
  • Proteus Digital Health (US)
Corresponding author
Belknap, Robert
Venue
PLoS ONE
Published
2013-01-07
Volume
8
Issue
1
Pages
e53373
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1988611386
Cited by
160
References
18
Citations by year
2026: 5 · 2025: 10 · 2024: 7 · 2023: 6 · 2022: 20 · 2021: 12 · 2020: 22 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 18 · 2015: 11 · 2014: 1 · 2013: 2
FWCI
9.05
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
  • Health Sciences › Health Professions › General Health Professions › Mobile Health and mHealth Applications
Keywords
tuberculosis, medication adherence, ingestible sensors, directly observed therapy, wearable sensors, detection accuracy, adverse events, body mass index
MeSH terms
Administration, Oral, Adult, Aged, Antitubercular Agents, Drug Administration Schedule, Feasibility Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Public Health, Sensitivity and Specificity, Tuberculosis, Pulmonary, Biosensing Techniques, Body Mass Index, Drug Monitoring, Directly Observed Therapy, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review